Tamiflu bolsters Chugai's first quarter but some underlying weakness
This article was originally published in Scrip
Executive Summary
A big increase in seasonal sales of the flu antiviral Tamiflu (oseltamivir) boosted the top line at Roche's Japanese affiliate Chugai in the first quarter ended 31 March, although there was some weakness in underlying performance due to a slow start for the long-acting erythropoiesis stimulating agent Mircera (peg-epoetin beta).